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Abstract
Diabetes is strongly linked to the development of Alzheimer’s disease (AD), though the mechanisms for this enhanced risk
are unclear. Because vascular inflammation is a consistent feature of both diabetes and AD, the cerebral microcirculation
could be a key target for the effects of diabetes in the brain. The goal of this study is to explore whether brain endothelial
cells, injured by diabetes-related insults, glucose and hypoxia, can affect inflammatory and activation processes in microglia
in vitro. Human brain microvascular endothelial cells (HBMVECs) were either treated with 5 mM glucose (control), 30 mM
glucose (high glucose), exposed to hypoxia, or exposed to hypoxia plus high glucose. HBMVEC-conditioned medium was
then used to treat BV-2 microglia. Alterations in microglia phenotype were assessed through measurement of nitric oxide
(NO), cytokine production, microglial activation state markers, and microglial phagocytosis. HBMVECs were injured by
exposure to glucose and/or hypoxia, as assessed by release of LDH, interleukin (IL)-1β, and reactive oxygen species (ROS).
HBMVECs injured by glucose and hypoxia induced increases in microglial production of NO, tumor necrosis factor-α
(TNFα) and matrix metalloproteinase (MMP)-9. Injured HBMVECs significantly increased microglial expression of CD11c
and CLEC7A, and decreased expression of the homeostatic marker P2RY12. Finally, bead uptake by BV-2 cells, an index
of phagocytic ability, was elevated by conditioned media from injured HBMVECs. The demonstration that injury to brain
endothelial cells by diabetic-associated insults, glucose and hypoxia, promotes microglial inflammation supports the idea
that the cerebral microcirculation is a critical locus for the deleterious effects of diabetes in the AD brain.
Keywords Vascular · Inflammation · Endothelial · Microglia · Alzheimer’s disease
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NOX	NADPH oxidase
TNFα	Tumor necrosis factor-α
MMP	Matrix metalloproteinase
MCP-1	Monocyte chemoattractant protein-1
ICAM-1	Intercellular adhesion molecule-1
CAP37	Cationic antimicrobial protein 37 kDa
NO	Nitric oxide
TGF-β	Transforming growth factor-β
IL	Interleukin
NVU	Neurovascular unit
DAM	Disease associated microglia
MGnD	Microglial neurodegenerative phenotype
CR1	Complement receptor 1
TREM2	Triggering receptor expressed on myeloid
cells 2
HBMVEC	Human brain microvascular endothelial cell
DMEM	Dulbeccos’s Modified Eagle Medium
Ab/Am	Antibiotic/Antimycotic
FBS	Fetal bovine serum
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BSA	Bovine serum albumin
LDH	Lactate dehydrogenase
RT	Room temperature
DCF-DA	2’,7’-Dichlorofluorescin diacetate
PBS	Phosphate buffered saline
ELISA	Enzyme linked immunosorbent assay
PFA	Paraformaldehyde
ANOVA	Analysis of variance
RNS	Reactive nitrogen species
iNOS	Inducible nitric oxide synthase
Aβ	Amyloid-β

Background
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by progressive loss of cognitive function, leading to dementia and death (Lane et al. 2018). AD is a complex, multifactorial disorder where disparate processes likely
converge to produce neuronal injury. Cardiovascular risk
factors (CVRFs) are important risk factors for the development of AD (Hofman et al. 1997; Helzner et al. 2009; Dickstein et al. 2010; Tolppanen et al. 2012; Yaffe et al. 2014). In
particular, individuals with type 2 diabetes mellitus (T2D)
have a greater than 50% increased risk for developing AD
( Ott et al. 1999; Janson et al. 2004; Gudala et al. 2013). In
the periphery, diabetes and other CVRFs are potent drivers
of inflammation (Lontchi-Yimagou et al. 2013). Because
neuroinflammation is a consistent feature of AD, and other
neurodegenerative diseases, inflammation could be a key
target for the effects of diabetes in the brain.
Sustained hyperglycemia, a pathognomonic feature of
diabetes, has been shown to drive endothelial cell dysfunction in the periphery via a number of signaling mechanisms,
including increased expression of reactive oxygen species
(ROS) and inflammatory proteins (Blake and Trounce
2014; Eelen et al. 2015; Stefano et al. 2016). Microvascular
endothelial cells at the blood-brain interface are the cells
in the brain most directly exposed to the deleterious effects
of high glucose levels. In this regard, both in vitro models
utilizing high glucose conditions and in vivo experiments
with diabetic animals have shown compromised blood-brain
barrier (BBB) integrity and increases in inflammatory proteins, including tumor necrosis factor-α (TNFα), and matrix
metalloproteinase (MMP)-9 (Bogush et al. 2017; Rom et al.
2019) .
There is a similar robust elevation in the expression of
inflammatory mediators in the cerebral microcirculation
in AD. AD brain endothelial cells express high levels of
inflammatory adhesion molecules, such as monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion
molecule-1 (ICAM-1), and cationic antimicrobial protein 37 kDa (CAP37) (Frohman et al. 1991; Pereira et al.
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1996; Grammas and Ovase 2001). Additionally, AD brain
microvessels release significantly higher levels of nitric
oxide (NO), thrombin, TNFα, transforming growth factor-β
(TGF-β), interleukin (IL) IL-1β, IL-6, IL-8, and MMPs
compared to age-matched controls (Dorheim et al. 1994;
Grammas and Ovase 2001; Grammas and Ovase 2002;
Thirumangalakudi et al. 2006). Because the inflamed/damaged cerebral endothelium is a highly synthetic interface
that produces numerous bioactive factors, it is likely that
endothelial-derived products will have critical effects on
neighboring cells of the neurovascular unit (NVU) (McConnell et al. 2017). The functional interaction of NVU cells
through bidirectional cell-cell signaling is critical for maintaining cerebral blood flow and regulating physiologic processes in the CNS (Muoio et al. 2014). Microglia-endothelial
cell cross-talk can influence BBB function and permeability
(Presta et al. 2018). For example, microglia activated by
treatment with LPS can induce alterations in brain endothelial cell morphology and function (Dudvarski Stankovic
et al. 2016), but less is known about endothelial cell effects
on microglia.
Microglia, the brain’s resident immune cells, are key
drivers of the neuroinflammatory response in AD and other
neurodegenerative disorders (Akiyama et al. 2000; Calsolaro
and Edison 2016). Once described as existing in a quiescent
or resting state, microglia are now understood to be dynamic
cells that are constantly surveying their microenvironment
for injury-inducing mediators (Hanisch and Kettenmann
2007). Microglia are believed to assume a diversity of phenotypes in response to noxious extracellular stimuli (Chitnis
and Weiner 2017; Hickman et al. 2018). Multiple groups
have identified a disease associated microglia (DAM) or
microglial neurodegenerative phenotype (MGnD), which
is present in AD (Keren-Shaul et al. 2017; Krasemann
et al. 2017). These DAM show decreased expression of
homeostatic microglia genes, including p2ry12/p2ry13 and
tmem119, and increased expression of pro-inflammatory and
AD-associated genes, including apoe, clec7a, and cd11c.
Additionally, proliferation and activation of microglia in the
brain, concentrated around amyloid plaques, is a prominent
feature of AD (Matsuoka et al. 2001; Fakhoury 2018), and
a number of recently identified AD-risk genes are related
to regulation of microglia and the innate immune system,
including triggering receptor expressed on myeloid cells 2
(TREM2) (Jones et al. 2010; Guerreiro et al. 2013; Jonsson
et al. 2013; Lambert et al. 2013). These findings suggest that
shifts in microglia function and phenotype are a key part of
the pathological development of AD.
The goal of this study is to explore whether injured
brain endothelial cells can affect inflammatory and activation processes in microglia. In our in vitro system, cultured
brain endothelial cells are injured by exposure to stimuli
that are important in the development of diabetic pathology,
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namely high glucose and hypoxia. The ability of conditioned
media from these injured endothelial cells to alter microglial
inflammatory proteins, activation markers, and phagocytic
activity is assessed in order to test the hypothesis that brain
endothelial cell injury will promote pro-inflammatory activation of microglia.

Methods
Cell Culture and Other Reagents
Human brain microvascular endothelial cells (HBMVECsACBRI 376) and complete medium with recombinant
growth factors (4Z0-500) were purchased from Cell Systems
(Kirkland, WA, USA). Murine immortalized microglia (BV2) were kindly provided by Dr. Navindra Seeram (University
of Rhode Island, Kingston, RI, USA). Low-glucose Dulbecco’s Modified Eagle Medium (DMEM), cell culture grade
D-glucose (glucose), antibiotic/antimycotic (Ab/Am), Fetal
Bovine Serum (FBS), and Bovine Serum Albumin (BSA)
were purchased from Sigma Aldrich (St. Louis, MO, USA).

Culture and Treatment of HBMVECs and BV‑2
HBMVECs were grown to confluence in culture in complete medium in accordance with protocols described by
Cell Systems and maintained at 37 °C in 5% CO2 in complete medium. Media was switched to low glucose (5mM)
DMEM with 1% BSA for treatments. HBMVECs were incubated with low glucose (5mM) (control) or high glucose
(30mM) in treatment media for 6 h. Cells were maintained
in normoxia for the full 6 h, or were exposed to hypoxic
(1% O2) conditions for the final 1 h of treatment. Following
treatment, conditioned media were collected and centrifuged
briefly at 1000×g in sterile conditions to pellet debris, and
used for subsequent treatment of BV-2.
BV2 were maintained at 37 °C in 5% CO2 in low glucose
(5mM) DMEM with 10% FBS, 1% Ab/Am, and 250 nM
L-glutamine added. HBMVEC-conditioned media was used
to treat BV-2 for 24 h. Conditioned media were collected
following endothelial cell treatment with either 5 mM glucose (6 h) (EC-C), 30 mM glucose (6 h) (EC-G), exposure
to hypoxia (1 h) (EC-H), or exposure to hypoxia plus high
glucose (6 h) (EC-G+H).

Cytotoxicity Assay
Cellular damage of HBMVECs was assessed by measuring lactate dehydrogenase (LDH) release in the conditioned
medium. Following treatment, supernatant was transferred
to a clear 96-well plate and total LDH was assessed using
the cytotoxicity detection kit (Millipore Sigma, Burlington,

MA, USA). Absorbance values were read at 490nm following incubation with supplied chromogenic dye and catalyst
using a Synergy HTX multi-mode reader (Biotek Instruments, Winooski, VT, USA).

Detection of Reactive Oxygen Species (ROS)
The production of ROS by HBMVECs was determined by a
fluorescent probe, 2’,7’-Dichlorofluorescin diacetate (DCFDA), using a previously described method with modification (Ma et al. 2017). HBMVECs were seeded in a blackwalled, clear-bottom 96-well plate at a density of 100,000
cells per mL and allowed to grow for 36 h. Cells were then
treated as previously described with high glucose with or
without hypoxia for 6 h. Following the 6 h treatment, DCFDA (10µM) was added to each well and incubated at 37 °C
in the dark for 25 min (min). Cells were washed 3 times with
phosphate buffered saline (PBS). The fluorescence signal of
each well was measured at 495 nm (excitation) and 529nm
(emission) using a SpectraMax M2 plate reader (Molecular
Devices, Sunnyvale, CA, USA).

Griess Assay
The production of NO was determined using the Griess
reagent system. BV-2 were grown in clear 24-well plates
at 100,000 cells/mL. Following treatment with HBMVECconditioned media for 24 h, culture media was transferred
to a clear 96-well plate and total NO was assessed using the
Griess reagent kit (Promega, Fitchburg, WI, USA). Absorbance values were read at 535nm using a Synergy HTX multimode reader (Biotek Instruments, Winooski, VT, USA).

Western Blot
Following treatments, BV-2 cells were rinsed in ice-cold
PBS and lysed in 10mM Tris-HCl, 150mM NaCl buffer containing protease inhibitors. Lysates were mixed with 40% 4×
Sample Buffer (4× Laemmli Sample Buffer (BioRad, Hercules, CA, USA) with 10% 2-mercaptoethonal) and heated to
100 °C for 10 min. Samples were resolved by SDS-PAGE on
4–20% Novex gradient gels (Invitrogen, CA) transferred to
nitrocellulose membranes (iBlot, Invitrogen, Carlsbad, CA,
USA). Membranes were blocked in 5% BSA in Tris buffered
saline (TBS) containing 0.05% Tween-20. Primary antibodies for this study include iNOS (Abcam, MA; Ab15323,
1:250), CLEC7A (Novus Biologicals, CO; NBO1-45514,
1:500), P2RY12 (Novus Biologicals, CO; NBP1-69246,
1:500), CD11c (Novus Biologicals, CO; MAB6950, 1:250),
and β-actin (Santa Cruz, CA; AC-15, 1:10,000). Bound
antibody was detected using InfraRed detectable secondary
antibodies (LI-COR, NE; 1:10,000), using LI-COR Odyssey
infrared scanner for imaging (LI-COR, Lincoln, NE, USA).
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Blots were analyzed using NIH ImageJ software and normalized against the housekeeper protein.

Enzyme Linked Immunosorbent Assay (ELISA)
IL-1β was measured from HBMVEC-conditioned media,
and TNFα and IL-6 were measured from BV-2 supernatant, using Enzyme Linked Immunosorbent Assay (ELISA)
from Biolegend (San Diego, CA, USA; Human IL-1β cat.
#437004, Mouse TNFα cat. #430904, Mouse IL-6 cat.
#431304). The protocol provided by the manufacturer was
followed, without modifications. At the conclusion of the
assay, absorbance was detected at 570 nm and 450 nm using
Synergy HTX multi-mode reader (Biotek Instruments, Winooski, VT, USA).

Gelatin Zymography
Gelatin zymography was performed as previously described
(Thirumangalakudi et al. 2007) to assess the activity of
MMP-9 in BV-2 supernatant following treatments. Briefly,
samples were run on 10% Gelatin Zymogram Plus Protein
Gels (Invitrogen, Carlsbad, CA, USA). Following electrophoresis, gels were incubated at room temperature (RT) with
zymogram renaturing buffer (Novex, Carlsbad, CA, USA)
for 30 min, and then incubated with zymogram developing
buffer (Novex, Carlsbad, CA, USA) for 30 min. Gels were
further incubated with fresh developing buffer overnight at
37 °C. Gels were stained with Coomassie Blue R250 for
1 h, and de-stained in deionized water for 1 day. Images
scanned on Epson Scanner (Epson, Long Beach, CA, USA)
and analyzed using ImageJ.

Phagocytosis Assay
Analysis of phagocytic activity of BV-2 was done by measuring uptake of fluorescently labeled beads. Protocol for the
phagocytosis assay was derived from previously published
works (Lucin et al. 2013; Lian et al. 2016; Cai et al. 2017;
Zhang et al. 2017) with modifications. BV-2 cells were
plated in 8-well chamber slides at a density of 10,000 cells
per well in DMEM with 10% FBS and grown for 48 h. Cells
were treated as before with HBMVEC-conditioned media
for 24 h.
Preopsonized latex beads of 1 um diameter (Sigma, cat.
#L2778-1ML) were prepared in PBS with 50% FBS at 10%
(v/v) for 1 h at 37 °C. Beads were then further diluted 1:100
in DMEM to make a 0.01% (v/v) beads and 0.05% (v/v)
FBS solution.
At the conclusion of 24 h treatment, BV-2 media was
removed and 500 uL of bead solution was added to each well
for 1 h at 37 °C. Beads were then removed and cells were
rinsed three times with cold PBS. Cells were fixed with 4%
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paraformaldehyde (PFA) in PBS (200 uL per well) for 4 min
at RT. PFA was removed, cells were then blocked and permeabilized with 5% horse serum and 0.3% Triton X-100 in
PBS (200 uL per well) for 30 min at RT. Cells were washed
again with cold PBS three times.
To image, antifade mounting solution with DAPI (Invitrogen, cat. #S36964) was added, slide was covered with a
cover slip, and sealed. Beads were imaged at 575–610nm
(red) and DAPI at 345–453 nm (blue) using the EVOS®
FL Auto Cell Imaging System (ThermoFisher Scientific,
Waltham, MA, USA). ImageJ was used to quantify red/blue
in all images.

Statistical Analysis
Data were analyzed for significance using one-way analysis
of variance (ANOVA) and multiple comparisons carried out
using the post-hoc Bonferroni test on GraphPad Prism (version 8.01). Data are represented as Mean +/− SEM. Groups
contain n = 6 unless otherwise specified.

Results
Injury of Brain Endothelial Cells by Exposure to High
Glucose Levels and Hypoxia
HBMVECs were either treated with 30 mM glucose (6 h),
exposed to hypoxia (1 h), or exposed to hypoxia plus high
glucose (6 h). LDH release in the supernatant was measured to estimate lethal cell injury. Treatment of cells with
glucose evoked a small but not significant increase in LDH
release. In contrast, hypoxia exposure significantly increased
LDH release compared to untreated controls (p < 0.001).
The level of LDH detected in cells exposed to hypoxia plus
high glucose was higher than levels measured in response to
hypoxia alone (Fig. 1a).
To explore indices of non-lethal injury the generation of
ROS and release of the inflammatory mediator IL-1β were
assessed. HBMVECs analyzed using the fluorescent probe
DCF-DA to measure ROS showed that glucose treatment did
not alter ROS production compared to control cells, while
hypoxia exposure increased ROS levels relative to control,
but the increase was not significant. HBMVECs exposed
to both glucose and hypoxia showed significantly increased
production of ROS compared to control (p < 0.001), glucose
(p < 0.001), or hypoxia (p < 0.05) (Fig. 1b). Measurement
of IL-1β levels in supernatant by ELISA indicated that treatment with glucose increased IL-1β levels, but the increase
was not significant (p = 0.11), while hypoxia exposure did
not affect IL-1β levels. Interestingly, the combination of glucose treatment and hypoxia exposure appeared to mitigate
the increase evoked by glucose alone (Fig. 1c).
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Fig. 1  HBMVEC injury following treatment with high glucose with
and without hypoxia HBMVECs were exposed to high glucose (6 h),
hypoxia (1 h), or a combination of both (6 h). Cells and supernatant
were collected to assess measures of cellular injury: a lactate dehydrogenase (LDH) release as a measure of cell toxicity, b reactive oxy-

gen species (ROS) production measured with DCF-DA, represented
as relative fluorescence units (RFU), and (C) IL-1β secretion in the
supernatant measured by ELISA. ***p < 0.001 vs. Control, ###p <
0.001 vs. Glucose, ^p < 0.05 vs. Hypoxia

Injured Brain Endothelial Cells Increase Reactive
Nitrogen Species Production in BV‑2 Cells

endothelial cells exposed to both glucose and hypoxia (ECG+H) significantly increased NO production compared to
BV-2 cells exposed to conditioned media from only glucosetreated endothelial cell cultures (p < 0.001). There was no
significant difference in BV-2 iNOS levels evoked by conditioned media from endothelial cells treated with glucose
alone and media derived from endothelial cells exposed to
both glucose and hypoxia (Fig. 2b).

To determine whether injured endothelial cells can affect
reactive nitrogen species (RNS) generation in microglia,
the microglial cell line BV-2 was treated with HBMVECconditioned media for 24 h. The Griess assay was used to
assess NO production in the BV-2 supernatant (Fig. 2a) and
inducible nitric oxide synthase (iNOS) levels in BV-2 lysates
were analyzed by western blot (Fig. 2b).
BV-2 cells exposed to conditioned media from glucosetreated endothelial cell cultures (EC-G) showed a significant
increase in both NO production (p < 0.001) (Fig. 2a) and
iNOS expression (p < 0.001) (Fig. 2b) compared to BV-2
cells incubated with untreated endothelial cell conditioned
media. In contrast, treatment of BV-2 cells with conditioned
media from hypoxia-exposed endothelial cells (EC-H) did
not affect either NO production or iNOS levels (Fig. 2a,
b). Treatment of BV-2 cells with conditioned media from

Glucose‑Injured Microvascular Endothelial Cells
Induce Changes in Inflammatory Proteins Released
from BV‑2 Cells
The release of cytokines, TNFα and IL-6, by BV-2 cells
treated with HBMVEC-conditioned media for 24 h was
assessed by ELISA.
BV-2 cells that were treated with media from glucoseinjured endothelial cells (EC-G) released a significantly
(p < 0.001) higher level of the pro-inflammatory cytokine

Fig. 2  HBMVEC injury
induces increased nitric oxide
production by BV-2 microglia Conditioned media from
injured HBMVECs was used to
treat BV-2 microglia for 24 h.
Supernatant and cell lysate were
collected following treatments
and used to measure (a) Nitric
Oxide (NO) in the supernatant
using Griess reagent (n = 12
per group) and (b) expression of
iNOS in the lysate by western
blot. **p < 0.01 vs. Control,
***p < 0.001 vs. Control, ###p
< 0.001 vs. Glucose, ^p < 0.05
vs. Hypoxia, ^^^p < 0.001 vs.
Hypoxia.
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TNFα compared to microglial cells exposed to control
conditioned media (Fig. 3a). On its own, conditioned
media from hypoxic-injured endothelial cells (EC-H) did
not alter BV-2 production of TNFα. However, media from
endothelial cells that were exposed to both glucose and
hypoxia (EC−G+H) increased TNFα production in BV-2
to higher levels than elicited by media from glucose-only
injured endothelial cells (p < 0.001) (Fig 3a).
In contrast to the results obtained for TNFα, the data
showed that conditioned media from glucose-injured
endothelial cells (EC-G) caused a significant (p < 0.001)
decrease in the release of IL-6, a complex cytokine with
both pro- and anti-inflammatory activities (Fig. 3b). Conditioned media from hypoxic-injured endothelial cells
(EC-H) did not affect BV-2 IL-6 levels. Also, media from
endothelial cells exposed to both glucose and hypoxia
(EC−G+H) showed a decrease in IL-6 release that was
comparable to that observed for glucose alone (EC-G)
(Fig. 3b).
Supernatant from BV-2 cells was collected following
treatment with HBMVEC-conditioned media for 24 h, as
described above, and MMP-9 activity measured by gel
zymography. Conditioned media from hypoxia exposed
endothelial cells (EC-H) did not affect MMP-9 activity
(Fig. 3c). There was a significant (p < 0.001) increase
in MMP-9 activity, relative to controls, elicited media
from glucose only (EC−G) and glucose plus hypoxia
(EC−G+H) (Fig. 3c).

BV-2 cells were treated with HBMVEC-conditioned media
for 24 h, as described above, and western blot used to determine changes in protein expression for several microglia
activation- and DAM-related markers.
Changes in the expression of CD11c and CLEC7A by
BV-2 in response to endothelial cell conditioned media were
similar in pattern, differing slightly in magnitude. Conditioned media from glucose-injured endothelial cells (ECG) significantly increased expression of CD11c (p < 0.01)
(Fig. 4a) and CLEC7A (p < 0.01) (Fig. 4b) as did conditioned media from glucose plus hypoxia injury (EC-G+H)
for both CD11c (p < 0.01) and CLEC7A (p < 0.05). Exposure of BV-2 cells to HBMVEC-conditioned media collected
as described above did not affect expression of TREM2 (data
not shown).
Western blot was also used to assess the expression of
a homeostatic microglia marker, P2RY12. Expression
of P2RY12 was significantly decreased when BV-2 cells
were treated with media from glucose injury (EC-G) (p <
0.001), hypoxic injury (EC-H) (p < 0.01), or glucose plus
hypoxic injury (EC-G+H) (p < 0.001) compared to controls
(Fig. 4c). Together, these changes indicate a shift towards a
DAM phenotype in the BV-2 treated with conditioned media
from damaged brain endothelial cells.

Fig. 3  HBMVEC injury induces increased production of inflammatory mediators by BV-2 microglia Conditioned media from injured
HBMVECs was used to treat BV-2 microglia for 24 h. Supernatant
from BV-2 was collected following treatments. ELISA was used to

measure secretion of (a) TNFα and (b) IL-6. (c) The enzymatic activity of MMP-9 was measured by gel zymography (n = 3 per group).
***p < 0.001 vs. Control, ###p < 0.001 vs. Glucose, ^^^p < 0.001 vs.
Hypoxia.
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Fig. 4  BV-2 treated with conditioned media from injured HBMVEC
show altered expression of microglia activation markers Conditioned
media from injured HBMVECs was used to treat BV-2 microglia for
24 h. Western blot was used to assess the expression of microglia

markers, (a) CD11c, (b) CLEC7A, and (c) P2RY12. *p < 0.05 vs.
Control, **p < 0.01 vs. Control, ***p < 0.001 vs. Control, ^p < 0.05
vs. Hypoxia, ^^p < 0.01 vs. Hypoxia

The Phagocytic Ability of BV‑2 Cells is Altered
in Response to Conditioned Media from Injured
Endothelial Cells

are consistent with literature documenting elevated MMP-9
in AD (Lorenzl et al. 2003). These results suggest that an
injured endothelium may promote the transition of microglia
toward an inflammatory phenotype.
Microglia were previously classified dichotomously into
M1 and M2 phenotypes using Iba1 as a marker to identify
“activated” microglia (Ito et al. 1998). Based on comprehensive gene expression profiling and functional studies,
a more fluid spectrum of activation states has been recognized to exist, with the DAM phenotype identified in the
AD brain. The DAM phenotype exhibits downregulation of
homeostatic microglia genes and upregulation of pro-inflammatory and neurodegeneration-associated genes (KerenShaul et al. 2017; Krasemann et al. 2017). Our findings that
injured endothelial cells significantly increase microglial
expression of DAM-related markers CD11c and CLEC7A,
as well as decrease expression of the homeostatic marker
P2RY12, suggest conversion of microglia towards a DAMlike phenotype.
Interestingly, treatment of microglial cultures with conditioned media from injured endothelial cells did not affect
the expression of TREM2. Although mutations in TREM2
are related to increased AD risk, its precise role is unclear
(Jay et al. 2017). One could interpret the lack of effect on
TREM2 as a peculiarity related to BV-2 cells and not indicative of microglia in vitro or in vivo. Although there are
limitations in using an immortalized cell system to approximate primary cell behavior in vitro, BV-2 cells have been
shown to closely model the inflammatory response of primary microglia in vitro (Stansley et al. 2012). In addition,
the response of BV-2 cells to LPS has substantial overlap
to the response of primary cultured microglia as well as to
that of microglia in vivo (Henn et al. 2009). A recent study
documented that conversion of microglia to the DAM phenotype occurs in a TREM-independent phase followed by a

BV-2 cells were treated for 24 h with HBMVEC-conditioned media, as described above, and uptake of fluorescently labeled beads measured to assess phagocytic ability (Fig. 5a and b). Bead uptake by BV-2 cells treated with
glucose injury media (EC-G) was significantly increased
(p < 0.05) compared to controls. In contrast, conditioned
media from hypoxic injury (EC−H) did not significantly
alter phagocytic ability of BV-2 cells. However, treatment
of BV-2 with conditioned media from glucose plus hypoxia
injury (EC−G+H) significantly (p < 0.001) reduced the
phagocytic response compared to glucose injury alone conditioned media (EC-G) (Fig. 5c).

Discussion
The results of this study demonstrate that injured brain
endothelial cells can negatively impact the inflammatory/
activation state of microglia. These data highlight the importance of cellular cross-talk in the brain, especially among
cells in the NVU. The ability of injured endothelial cells to
induce changes in microglia, consistent with microglia alterations observed in AD, suggests that this cell-cell interaction
is contributory to the development of pathology in AD.
Our data show that brain endothelial cells injured by glucose and hypoxia induce increases in microglial production
of NO and TNFα. These inflammatory mediators have been
well documented to be elevated in the AD brain in several
cell types, including microglia (Hickman et al. 2018). Similarly, our results showing increases in microglial MMP-9
expression by injured endothelial cell conditioned media
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Fig. 5  BV-2 treated with conditioned media from injured HBMVEC
show altered phagocytic ability Conditioned media from injured
HBMVEC was used to treat BV-2 microglia for 24 h. BV-2 were then
incubated with fluorescently labeled beads for 1 h. Cells were then

imaged (EC-C, EC-G, EC-H, EC-G+H left to right) at 10X (a) and
20X (b) and bead uptake per cell was quantified (c) as a measure of
phagocytic activity. *p < 0.05 vs. Control, ###p < 0.001 vs. Glucose.

TREM-dependent phase (Keren-Shaul et al. 2017). It is possible that in our study the transition to the DAM phenotype
is not yet complete.
Phagocytosis is a key aspect of microglial function in
the healthy brain, responsible for clearance of debris,
apoptotic cells, and synaptic pruning (Fu et al. 2014; Hickman et al. 2018). In AD, phagocytic microglia may help
to clear aggregated amyloid-β (Aβ) and be beneficial (Fu
et al. 2014). In this regard, increased phagocytic activity is
correlated with enhanced production of anti-inflammatory
and reduced production of pro-inflammatory mediators in
microglia and macrophages (Fadok et al. 1998; Wolf et al.
2017; Janda et al. 2018). However, there is still some debate
as to whether microglia phagocytosis is beneficial or detrimental in disease. For example, TREM2 mediated phagocytosis of apoptotic neurons is associated with decreased
a decreased pro-inflammatory response (Takahashi et al.
2005), while myelin debris phagocytosis enhanced the proinflammatory and dampened the anti-inflammatory profile

in microglia (Siddiqui et al. 2016). TREM2 knock out mice
have impaired phagocytosis, related to increased Aβ plaque
burden, reduced microglia localization to plaques, and
increased neuritic dystrophy ( Jay et al. 2017; Hickman et al.
2018). DAM exhibit upregulation of phagocytosis-related
genes (Keren-Shaul et al. 2017), while other studies indicate that an anti-inflammatory DAM sub-type highly express
phagocytosis-associated genes (Rangaraju et al. 2018). Here,
the response of BV-2 cells to conditioned media from injured
endothelial cells appears to be related to the nature of the
endothelial insult. The data show that microglial phagocytosis is increased in response to conditioned media from
glucose-injured endothelial cells. In contrast, conditioned
media from hypoxia-injured endothelial cells does not
significantly alter phagocytosis and further, media from
glucose plus hypoxic injured endothelial cells reduces the
increase in phagocytosis evoked by glucose alone. These
data are similar to the results showing that glucose but not
hypoxia increases IL-1β release from endothelial cells and
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that concurrent hypoxia plus glucose reduces the increase
in IL-1β produced by glucose alone. These results support
the idea that IL-1β from injured endothelial cells promotes
increased phagocytosis by microglia. Other studies have
also linked IL-1β to increased microglial phagocytosis as
well as to microglial autophagy, a process closely linked
to phagocytosis (Ferreira et al. 2011; François et al. 2013;
Plaza-Zabala et al. 2017).
Considerable evidence documents an injured cerebrovasculature in AD (Grammas 2011). We have previously
shown that damaged brain endothelial cells secrete a number of factors that have been related to neuroinflammation
and the activation of pro-inflammatory microglia, including thrombin, MMPs, and a number of cytokines (Grammas
and Ovase 2001; Grammas and Ovase 2002; Grammas et al.
2004; Grammas et al. 2011; K Lee et al. 2015; Krasnow
et al. 2017). Our findings indicate a role for vascular-derived
IL-1β and ROS in propagating the inflammatory cycle in the
brain. Here, brain endothelial cells injured by glucose and
glucose plus hypoxia exhibit an upregulation in IL-1β and
ROS, respectively, and these increases were correlated with
the up-regulation of pro-inflammatory markers in microglia. IL-1β acts as an amplifier of immune reactions and can
stimulate a number of downstream neuroinflammatory processes. In the periphery, IL-1β stimulated the differentiation
of monocytes to M1-like macrophages (Bent et al. 2018).
In vitro, IL-1β enhanced microglia release of NO following
LPS stimulation (Possel et al. 2000). High levels of oxidative
stress have been identified in the AD brain, and ROS function as mediators of injury and inflammation (Fischer and
Maier 2015). ROS-mediated signaling pathways are relevant
for the induction of inflammatory signaling, including the
stimulation of pro-inflammatory cytokines and NO (Fischer
and Maier 2015). TNFα, NO, and MMP-9 are all produced
in response to both oxidative stress and cytokine signaling
(Yong et al. 2001; Clark et al. 2010; Hsieh and Yang 2013;
Fischer and Maier 2015), highlighting the potential for these
endothelial-derived mediators to activate a pro-inflammatory
response in microglia similar to that shown in our in vitro
system.
Endothelial cells may react to injurious stimuli such as
glucose and hypoxia by activating multiple signaling pathways resulting in the release of diverse mediators (Eelen
et al. 2015). In some instances, these mediators could synergize, as we observed for NO release by microglia which was
higher when treated with conditioned media from glucose
plus hypoxic injury compared to glucose alone. In contrast,
the combination of hypoxic and glucose injury reduced the
increase in microglial phagocytosis evoked by glucose-only
injured endothelial cells. Finally, the responses of cytokines
as a family may also vary with individual proteins. In this
regard, while TNFα expression by microglia was increased
by glucose-injured endothelial cells, IL-6 expression was

significantly inhibited. Although mostly regarded as a proinflammatory cytokine, IL-6 also has many regenerative or
anti-inflammatory activities (Scheller et al. 2011). The pleiotropic actions of IL-6 as both a proinflammatory mediator as
well as a neurotrophic factor involved in the physiological
homeostasis of the CNS further highlight the complexity
of cellular responses in the presence of multiple bioactive
moieties.
The relationship between brain endothelial cells and
microglia is a growing area of interest, with early findings
indicating that damage to brain endothelial cells by a number of mediators can induce an inflammatory response in
microglia. Microglia treated with conditioned media from
IL-1-treated endothelial cells exhibit increased expression of
inflammatory mediators, including IL-1β, IL-6, and CCL2
(Zhu et al. 2019). Treatment of microglia with conditioned
media from brain endothelial cells exposed to oxygenglucose deprivation (OGD) exhibited increases in cytokine
release, including TNFα, IL-1β, and IL-10. These microglia additionally exhibited upregulated iNOS expression and
impaired phagocytosis (Xing et al. 2018). The OGD-related
findings mirror our results in the EC-G and EC-GH microglia treatment groups, particularly with respect to increases
in TNFα and iNOS, as well as altered phagocytic ability.
Together, these studies further support our hypothesis that
the damaged cerebrovasculature can be a driver of inflammation in the brain, and indicate that damage by different
mediators may activate diverse inflammatory responses in
microglia.

Conclusions
The results of this study are important as they shed light on
the interaction of two cell types, endothelial cells and microglia, likely important in the development of AD pathology.
The role of specific mediators in this cell-cell communication is difficult to ascribe because of the inherent limitations
of using a simplified in vitro system. Nevertheless, the demonstration that injury to brain endothelial cells by glucose
and hypoxia, two insults that are relevant for diabetes, affects
processes in microglia that are relevant for AD, support the
hypothesis that the cerebral microcirculation could be a
nidus where diabetic processes promote the development of
AD. A more in-depth investigation of how endothelial cell
damage can alter microglia function and lead to an inflammatory response may help us to better understand the neuroinflammation found in AD and other neurodegenerative
disorders. Additionally, greater knowledge of the mediators responsible for this endothelial cell-microglia crosstalk
could inform novel therapeutic targets and techniques for
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mitigating disease-related inflammation at its potential point
of origin, the vasculature.
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